Co-Authors
This is a "connection" page, showing publications co-authored by CHARLOTTE C SUN and LARISSA ALEJANDRA MEYER.
Connection Strength
5.980
-
Healthcare Costs in the United States by Demographic Characteristics and Comorbidity Status. Value Health. 2024 Nov 10.
Score: 0.248
-
Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021. Gynecol Oncol. 2024 Nov; 190:255-261.
Score: 0.245
-
Cost of ovarian cancer by the phase of care in the United States. Am J Obstet Gynecol. 2024 Aug 17.
Score: 0.244
-
Determination of quality of life-related health utilities for surgical complications in ovarian cancer. Gynecol Oncol. 2024 06; 185:101-107.
Score: 0.236
-
Secondary validation of an ovarian cancer-specific comorbidity index in a US population. Int J Gynecol Cancer. 2023 05 01; 33(5):749-754.
Score: 0.223
-
Predicting 180-day mortality for women with ovarian cancer using machine learning and patient-reported outcome data. Sci Rep. 2022 12 08; 12(1):21269.
Score: 0.217
-
Medicaid Expansion and Postoperative Mortality in Women with Gynecologic Cancer: A Difference-in-Difference Analysis. Ann Surg Oncol. 2023 Mar; 30(3):1508-1519.
Score: 0.215
-
Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States. Int J Gynecol Cancer. 2022 09 06; 32(9):1153-1163.
Score: 0.213
-
Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States. Int J Gynecol Cancer. 2022 07 04; 32(7):899-905.
Score: 0.211
-
Medicaid expansion and 2-year survival in women with gynecologic cancer: a difference-in-difference analysis. Am J Obstet Gynecol. 2022 09; 227(3):482.e1-482.e15.
Score: 0.208
-
Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data. JCO Clin Cancer Inform. 2022 03; 6:e2100187.
Score: 0.206
-
Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States. Cancer. 2021 Nov 15; 127(22):4151-4160.
Score: 0.198
-
Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol. 2021 07; 225(1):68.e1-68.e11.
Score: 0.191
-
Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 04; 161(1):56-62.
Score: 0.191
-
National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer. 2020 08; 30(8):1195-1202.
Score: 0.183
-
Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. Int J Gynecol Cancer. 2020 02; 30(2):187-192.
Score: 0.176
-
Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes. Gynecol Oncol. 2019 08; 154(2):405-410.
Score: 0.170
-
National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia. Am J Obstet Gynecol. 2019 11; 221(5):474.e1-474.e11.
Score: 0.170
-
Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol. 2019 08; 221(2):136.e1-136.e9.
Score: 0.168
-
National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. Gynecol Oncol. 2019 03; 152(3):439-444.
Score: 0.167
-
Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol. 2019 03; 152(3):501-508.
Score: 0.167
-
Women's preferences for cancer risk management strategies in Lynch syndrome. Gynecol Oncol. 2019 03; 152(3):514-521.
Score: 0.167
-
Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol. 2018 11; 151(2):269-274.
Score: 0.162
-
Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol. 2018 07; 132(1):52-58.
Score: 0.160
-
Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol. 2018 09; 150(3):451-459.
Score: 0.159
-
Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol. 2017 04; 145(1):55-60.
Score: 0.145
-
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 11 10; 34(32):3854-3863.
Score: 0.142
-
The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. Expert Rev Qual Life Cancer Care. 2016; 1(3):231-238.
Score: 0.138
-
Avoidable tragedies: Disparities in healthcare access among medically underserved women diagnosed with cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):500-5.
Score: 0.132
-
Effect of Medicaid expansion on cancer treatment and survival among Medicaid beneficiaries and the uninsured. Cancer Med. 2024 Jul; 13(13):e7461.
Score: 0.060
-
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.
Score: 0.058
-
Impacts of Medicaid Expansion on Stage at Cancer Diagnosis by Patient Insurance Type. Am J Prev Med. 2022 12; 63(6):915-925.
Score: 0.053
-
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
Score: 0.050
-
Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018 06; 149(3):484-490.
Score: 0.039
-
Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer. 2018 02; 28(2):285-292.
Score: 0.039
-
Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
Score: 0.038
-
Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1427-1433.
Score: 0.036
-
The DISINFECT Initiative: Decreasing the Incidence of Surgical INFECTions in Gynecologic Oncology. Ann Surg Oncol. 2017 Feb; 24(2):362-368.
Score: 0.035
-
Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):553-8.
Score: 0.033
-
Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv. 2016 Apr; 10(2):261-70.
Score: 0.033
-
Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecol Oncol. 2015 Sep; 138(3):727-30.
Score: 0.032
-
Survival after intestinal perforation: can it be predicted? Gynecol Oncol. 2009 Dec; 115(3):349-53.
Score: 0.022